Secondary glaucoma after bevacizumab injection in Type-1 retinopathy of prematurity
Purpose: The authors report three separate cases of type 1 retinopathy of prematurity (ROP) treated with intravitreal bevacizumab before, or at 34 weeks postmenstrual age (PMA), with subsequent development of secondary glaucoma. Observations: All three cases involve patients born ≤24 weeks and meeti...
Saved in:
Main Authors: | Anthony A. Jones, Jacob S. Martin, Annette L. Giangiacomo, Deborah M. Costakos |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-12-01
|
Series: | American Journal of Ophthalmology Case Reports |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2451993624001415 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Comparison of reactivation between ranibizumab and bevacizumab in aggressive retinopathy of prematurity: A retrospective case series
by: Anil Babanrao Gangwe, et al.
Published: (2025-01-01) -
The macular microvascular changes in children with a history of retinopathy of prematurity treated with intravitreal Bevacizumab injection using optical coherence tomography angiography: a retrospective cohort
by: Amir Eftekhari Milani, et al.
Published: (2024-11-01) -
Early postoperative bevacizumab for preventing neovascular glaucoma in phacovitrectomy for proliferative diabetic retinopathy
by: Sunjin Hwang, et al.
Published: (2025-01-01) -
Treatment of aggressive posterior retinopathy of prematurity accompanied by nasolacrimal duct obstruction with purulent discharge: A case report
by: Ehsan Namvar, et al.
Published: (2024-11-01) -
Analysis of Salivary Cytokines in Retinopathy of Prematurity
by: Hwa-Shiu Wu, et al.
Published: (2025-01-01)